Noninvasive Biomarkers of Liver Fibrosis: An Overview

Table 2

AUROC for the indirect markers that have been used in assessment of fibrosis in various liver diseases.

Marker	Liver disease evaluated by various markers				AURCO for advanced fibrosis	AURCO for cirrhosis	References
	CHC	CHB	NAFLD	ALD
ALT (2.25) the normal	0.716–0.815				0.716–0.815	—	[75, 163]
AST/ALT ratio	0.54–0.709	NA	0.742–0.83	NA	0.54–0.83	0.67	[78, 80, 112, 114, 155, 162, 164]
APRI	0.65–0.87	0.67–0.72	0.564–0.866	—	0.564–0.87	0.75–0.92	[79, 87–91, 112, 120, 150, 156, 164–167]
Frons index	0.78–0.86	NA	—	—	0.78–0.86		[94, 152]
PGAA index	—	—	—	NA	—	—	[95, 96]
Fibro test	0.72–0.87	0.76–0.85	0.82–0.89	0.83–0.91	0.72–0.87	0.77–0.94	[99–101, 104–106, 112, 120, 129, 152, 153, 159, 169, 170]
Acti test	NA		0.77 SH				[97, 105, 106]
Fibro index	0.804–0.83-	NA	—	—	0.82	0.845	[107, 108, 120, 164]
Fib-4*	0.785–0.86	0.81	—	—	0.785–0.86	—	[109–111, 114, 166]
FibroQ	0.789	NA; NA	—	—	0.783	0.791	[113, 114]
The simple test (NAFLD) fibrosis score	—	—	0.82–0.89	—	0.82–0.89	—	[116, 121, 131]
Steato test	—	—	0.799–0.86		0.799–0.86	—	[117]
SELDI-TOF protein chip	0.88	0.926	—	—	0.88–0.906	0.921	[137, 170]
13C metacetin breath test	0.83-	—	—	—	0.83	0.96	[133, 164]

∗Used to assess fibrosis in HCV/HIV coinfected patients.
NA: studied but AUROC is not available.